Wednesday, February 11, 2026

No Result

View All Result

Media

No Result

View All Result

Health

Appropriate medication use includes access to state-of-the-art drugs: Nigel Rawson and John Adams in National Newswatch

November 21, 2025

Nigel Rawson

Commentary

Waiting for new drugs for rare disorders in Canada

September 6, 2023

Inside Policy

Waiting for new drugs for rare disorders in Canada, part 8 – need for a national strategy: Nigel Rawson and John Adams for Inside Policy

August 30, 2023

Inside Policy

Waiting for new drugs for rare disorders in Canada, part 7 – Canadian Drug Agency: Nigel Rawson and John Adams for Inside Policy

August 23, 2023

Inside Policy

Waiting for new drugs for rare disorders in Canada, part 6 – national pharmacare: Nigel Rawson and John Adams for Inside Policy

August 16, 2023

Inside Policy

Waiting for new drugs for rare disorders in Canada, part 5 – Patented Medicine Prices Review Board: Nigel Rawson and John Adams for Inside Policy

August 9, 2023

Inside Policy

Waiting for new drugs for rare disorders in Canada, part 4 – government drug plan listing: Nigel Rawson and John Adams for Inside Policy

August 2, 2023

Inside Policy

Waiting for new drugs for rare disorders in Canada – part 3, price negotiation: Nigel Rawson and John Adams for Inside Policy

July 26, 2023

Inside Policy

Waiting for new drugs for rare disorders in Canada – part 2, health technology assessment: Nigel Rawson and John Adams for Inside Policy

July 19, 2023

Inside Policy

Waiting for new drugs for rare disorders in Canada – part 1, regulatory approval: Nigel Rawson and John Adams for Inside Policy

July 12, 2023

Time for the PMPRB to go: Nigel Rawson and Brett Skinner in the Hill Times

Columns

The PMPRB has outlived its usefulness: Nigel Rawson in the Hill Times

June 28, 2023

The Patented Medicine Prices Review Board is selling Canadians a lemon: Nigel Rawson for Inside Policy

Columns

Lower drug prices are a good thing. Canada’s approach to achieving them was not: Nigel Rawson in the Globe and Mail

March 17, 2023

The U.S. outsources control of drug prices to Canada: weird! Richard Owens in the Financial Post

Columns

The drug prices review board was once a solution. It’s now a problem: Nigel Rawson and John Adams in the Financial Post

March 1, 2023

Page 3 of 4 Prev 1 2 3 4 Next

Newsletter Signup

Email Address *

First Name *

Last Name *

*Required Fields

Follow us on

Macdonald-Laurier Institute

Support Us

Support the Macdonald-Laurier Institute to help ensure that Canada is one of the best governed countries in the world. Click below to learn more or become a sponsor.

Support Us

No Result

View All Result

Appropriate medication use includes access to state-of-the-art drugs: Nigel Rawson and John Adams in National Newswatch

Nigel Rawson

Waiting for new drugs for rare disorders in Canada

Waiting for new drugs for rare disorders in Canada, part 8 – need for a national strategy: Nigel Rawson and John Adams for Inside Policy

Waiting for new drugs for rare disorders in Canada, part 7 – Canadian Drug Agency: Nigel Rawson and John Adams for Inside Policy

Waiting for new drugs for rare disorders in Canada, part 6 – national pharmacare: Nigel Rawson and John Adams for Inside Policy

Waiting for new drugs for rare disorders in Canada, part 5 – Patented Medicine Prices Review Board: Nigel Rawson and John Adams for Inside Policy

Waiting for new drugs for rare disorders in Canada, part 4 – government drug plan listing: Nigel Rawson and John Adams for Inside Policy

Waiting for new drugs for rare disorders in Canada – part 3, price negotiation: Nigel Rawson and John Adams for Inside Policy

Waiting for new drugs for rare disorders in Canada – part 2, health technology assessment: Nigel Rawson and John Adams for Inside Policy

Waiting for new drugs for rare disorders in Canada – part 1, regulatory approval: Nigel Rawson and John Adams for Inside Policy

The PMPRB has outlived its usefulness: Nigel Rawson in the Hill Times

Lower drug prices are a good thing. Canada’s approach to achieving them was not: Nigel Rawson in the Globe and Mail

The drug prices review board was once a solution. It’s now a problem: Nigel Rawson and John Adams in the Financial Post

Top News

Charting uncertain waters – Facts vs. fears in indigenous land claim rulings: Panel discussion

The mainstream media failed Canadians during the Freedom Convoy: Peter Menzies in The Hub

U.S. think tank links CCP groups to entities in Canada

Multimedia

Breakthrough Nation with Karen Restoule: Thomas Isaac Series 3, Ep. 1

Breakthrough Nation with Karen Restoule: Crystal Smith Series 2, Ep. 8

Carney’s new world order—Is Canada ready to lead the middle powers?: Christian Leuprecht on The Paikin Podcast

What if Trump is painfully right?: Stephen Nagy for Inside Policy

Canada must settle the F-35 debate before Trump forces the issue: J.L. Granatstein for Inside Policy

A separate Alberta would be a poorer Alberta: Trevor Tombe in The Hub

Cancel the F-35? JAS 39 Gripen Fighter would cripple Canada’s Air Force: Rob Huebert and Jamie Tronnes for National Security Journal

Fixing Canada’s broken immigration system – Presenting more data to Parliament: Michael Barutciski

Newsletter Signup

Follow us on

Macdonald-Laurier Institute

Support Us